Intellia, LogicBio fuel hope for in vivo gene editing with new animal data in rare diseases: report

Facebook
Twitter
LinkedIn
Email
Print
Investor excitement over the development of products that can be injected directly into patients to correct inherited diseases, or “in vivo gene editing,” has largely been fueled over the past few months by Intellia Therapeutics and its experimental therapy NTLA-2001 to address the rare liver disease transthyretin (ATTR) amyloidosis. But Intellia’s huge run—its stock is up 70% year to date—has overshadowed some of the players in the field, including LogicBio Therapeutics, which has seen its shares lose half their value this year.

Investors may still be underestimating the potential of in vivo gene editing, however. That was the conclusion reached by analysts at Jefferies after they examined new animal data that Intellia and LogicBio presented at the European Society of Gene and Cell Therapy (ESGCT) conference last week.